At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
In Brief
A Phase 2 clinical trial evaluating 18F-AV-1451 for Frontotemporal Lobar Degeneration (FTLD) and 2 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Study Details
Timeline
Interventions
A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.